Tino Marcos Lino da Silva, Viviane Pinheiro Alves de Almeida, Antônio Kleiton de Sousa, Rafael da Silva Prudêncio, Maria da Graça Sales Furtado, Ana Clara Coelho da Costa, Vanderlene Oliveira Rodrigues, Danyela Maria Leal Holanda, João Janilson da Silva Sousa, Paulo Roberto Carneiro Gomes, Maria Vitória Pereira de Sousa, Daniel Fernando Pereira Vasconcelos, Carlos Eduardo da Silva Monteiro, Antonia Beatriz Alves Ferreira, Pedro Marcos Gomes Soares, Lidia Moreira Lima, Carlos Alberto Manssour Fraga, Eliezer Jesus de Lacerda Barreiro, Diva de Aguiar Magalhães, Tarcísio Vieira de Brito, André Luiz Dos Reis Barbosa
Pain and inflammation are protective responses; however, when persistent, they can cause damage and reduce the quality of life. The limitations of current therapies underscore the importance of investigating new agents that are effective and have fewer adverse effects. Therefore, the present study aimed to evaluate the anti-inflammatory and antinociceptive activities of LASSBio-753 in rats. The animals were pretreated with LASSBio-753 at doses of 0.1, 1.0, and 10 mg/kg, p.o., and subjected to carrageenan-induced paw edema to determine the optimal dose for combating inflammation caused by this agent. Subsequently, paw edema was induced using inflammatory mediators: histamine, compound 48/80, serotonin, prostaglandin E2, and bradykinin. Carrageenan-induced peritonitis was induced to assess neutrophil migration, as well as the levels of TNF-α, IL-1β, myeloperoxidase, malondialdehyde, and glutathione in the peritoneal fluid. Acetic acid-induced abdominal writhing and formalin-induced paw licking were used to evaluate antinociceptive activity. The 10 mg/kg dose of LASSBio-753 demonstrated the best anti-inflammatory and antinociceptive effects, reducing carrageenan-induced edema and edema induced by inflammatory mediators, as well as reducing neutrophil migration, TNF-α and IL-1β, myeloperoxidase, and malondialdehyde, while preserving glutathione in the peritoneal fluid. In addition, it reduced the number of abdominal contractions and the duration of paw licking that were chemically induced. The results obtained demonstrate that LASSBio-753 possesses significant anti-inflammatory and antinociceptive potential and may be a promising candidate for the treatment of inflammatory diseases; however, studies in inflammatory disease models are needed to better elucidate its therapeutic potential.